Elan Corporation, plc ELN (Elan or the Company) today advises
Elan Shareholders to withdraw any acceptances of Royalty Pharma's Offer
without delay and not to tender any further acceptances. Following the
outcome of the Elan EGM yesterday morning, and in accordance with the
terms of the Royalty Pharma Offer, the Royalty Pharma Offer has now
lapsed*.
Withdrawal of acceptances of the Royalty Pharma Offer will ensure that
Elan Shareholders are in a position to participate in the benefits of
the formal sale process which has now commenced. Elan's financial
advisers contacted Royalty Pharma's financial advisers over the weekend
of 15/16 June for the purpose of inviting Royalty Pharma to participate
in that process.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in